4.6 Article

Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD

期刊

BMJ OPEN
卷 11, 期 11, 页码 -

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2021-049740

关键词

-

资金

  1. Helmsley Charitable Trust [2003-04445]
  2. National Center for Advancing Translational Sciences [UL1TR002489, T32DK007634, K23KD111995-01A1]
  3. Pfizer
  4. Takeda
  5. Janssen
  6. Abbvie
  7. Eli Lilly
  8. Genentech
  9. Boehringer Ingelheim
  10. Bristol Myers Squibb
  11. Celltrion
  12. Arenapharm

向作者/读者索取更多资源

This study developed an individualised prognostic risk prediction tool for predicting adverse COVID-19 outcomes in patients with inflammatory bowel disease (IBD) using data from an international registry. The models showed excellent discrimination and can effectively predict higher risk for COVID-19-related adverse outcomes in this population, aiding in discussions of risks with healthcare providers.
Objectives Develop an individualised prognostic risk prediction tool for predicting the probability of adverse COVID-19 outcomes in patients with inflammatory bowel disease (IBD). Design and setting This study developed and validated prognostic penalised logistic regression models using reports to the international Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease voluntary registry from March to October 2020. Model development was done using a training data set (85% of cases reported 13 March-15 September 2020), and model validation was conducted using a test data set (the remaining 15% of cases plus all cases reported 16 September-20 October 2020). Participants We included 2709 cases from 59 countries (mean age 41.2 years (SD 18), 50.2% male). All submitted cases after removing duplicates were included. Primary and secondary outcome measures COVID-19 related: (1) Hospitalisation+: composite outcome of hospitalisation, ICU admission, mechanical ventilation or death; (2) Intensive Care Unit+ (ICU+): composite outcome of ICU admission, mechanical ventilation or death; (3) Death. We assessed the resulting models' discrimination using the area under the curve of the receiver operator characteristic curves and reported the corresponding 95% Cls. Results Of the submitted cases, a total of 633 (24%) were hospitalised, 137 (5%) were admitted to the ICU or intubated and 69 (3%) died. 2009 patients comprised the training set and 700 the test set. The models demonstrated excellent discrimination, with a test set area under the curve (95% CI) of 0.79 (0.75 to 0.83) for Hospitalisation+, 0.88 (0.82 to 0.95) for ICU+ and 0.94 (0.89 to 0.99) for Death. Age, comorbidities, corticosteroid use and male gender were associated with a higher risk of death, while the use of biological therapies was associated with a lower risk. Conclusions Prognostic models can effectively predict who is at higher risk for COVID-19-related adverse outcomes in a population of patients with IBD. A free online risk calculator (https://covidibd.org/covid-19-risk-calculator/) is available for healthcare providers to facilitate discussion of risks due to COVID-19 with patients with IBD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据